ENDPOINTS

Plus, news about Ake­so, Pul­ma­trix, Au­to­lus, Macro­Gen­ics and Bliss­Bio: Gen­fit com­pletes up to €185M roy­al­ty deal: Per the agree­ment with Health­Care Roy­al­ty, the com­pa­ny …

Plus, news about Cen­tu­ry Ther­a­peu­tics, Ake­bia Ther­a­peu­tics, Eye­n­ovia, Be­taliq, Alvotech, Genen­ta Sci­ence, Aa­di Bio­science, and Ex­i­cure: El­e­va­tion On­col­o­gy drops ADC, lays off 70%: The Boston

Plus, news about Pyx­is On­col­o­gy, Kiromic Bio­Phar­ma, TC Bio­Pharm, En­ter­o­Bi­otix, Liq­uidia, Com­pass Path­ways, Vin­cerx Phar­ma and Neur­i­zon: Em­press Ther­a­peu­tics un­der­goes lay­offs: A spokesper­son for the

Plus, news about Pil­lar, vTv Ther­a­peu­tics, OP­KO Health, En­tera Bio, Zen­tal­is, Sutro Bio­phar­ma and Idor­sia: Ver­tan­i­cal’s non-opi­oid painkiller suc­ceeds in Phase 3: The Ger­man biotech

Plus, news about Hei­del­berg, Ac­cropeu­tics, Al­lar­i­ty Ther­a­peu­tics, Ca­dren­al and In­ovio: Al­tim­mune to test its in­cretin in ad­dic­tion: Fol­low­ing the path set by No­vo Nordisk …

Plus, news about Har­bour Bio­Med: As­cle­tis’ mus­cle-pre­serv­ing drug yields limp weight loss da­ta: The Hong Kong-based biotech said its adi­pose-tar­get­ed obe­si­ty … Sign up to

Plus, news about BioN­Tech, Roche, Boehringer In­gel­heim, Cer­voMed, Gen­mab, In­ozyme Phar­ma, Va­lo Ther­a­peu­tics and Agomab: Min­eralys Ther­a­peu­tics’ $250M fol­low-on of­fer­ing: Stel­lar Phase … Sign up

Plus, news about Atea Phar­ma­ceu­ti­cals: Cy­tomX, Am­gen stop work on T cell en­gager: The part­ners de­cid­ed to end de­vel­op­ment of an … Sign up to

Plus, news about Tris Phar­ma and ARS Phar­ma­ceu­ti­cals: Mer­ck KGaA’s lu­pus drug yields mixed da­ta in mid-stage tri­al: The drug­mak­er’s TLR7/8 in­hibitor, called en­pa­toran …